Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2877)	3/27/2020 7:02:08 PM
From: CuttingEdge Bio	Read Replies (1) \| Respond to of 3557

"Cross reactivity (SARS/MERS) for ACE2/RBD binding assay was not observed, while for the viral binding assay (not viral neutralization assay, viral binding at distant epitopes, outside RBD) cross reactivity was partially demonstrated (SARS preferential)." I guess I'm just not seeing the significance of this. Maybe I'm not understanding the point being made. If someone is using covid19 pseudo virus to get mouse to make antibodies, as regeneron said they are doing, they will presumably be making antibodies not limited only to RBD. Any antibody candidate selected is going to be tested in multiple neutralization assays to make sure it really "works" on the virus before putting into clinic. I'm not seeing relevance of SARS or MERS to this.